Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2015 2
2016 2
2017 1
2021 1
2022 1
2023 1
2024 1
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma.
Smits F, Groen K, Levin MD, Stege CAM, van Kampen R, van der Spek E, Bilgin YM, Thielen N, Nijhof I, Ludwig I, de Waal EGM, Sandberg Y, Kentos A, Timmers GJ, Regelink JC, Westerman M, de Heer K, Vekemans MC, Durdu-Rayman N, de Graauw NCHP, Seefat MR, van de Donk NWCJ, Ypma PF, Nasserinejad K, Zweegman S. Smits F, et al. Among authors: de waal egm. Blood. 2025 Jan 30;145(5):543-546. doi: 10.1182/blood.2024025868. Blood. 2025. PMID: 39576961
Frail subgroups determine heterogeneous outcomes in older patients with NDMM - long-term follow-up of the HOVON 143 trial.
Smits F, Groen K, Levin MD, Stege CAM, van Kampen RJW, van der Spek E, Nijhof IS, Bilgin YM, Thielen N, Ludwig I, de Waal EGM, Sandberg Y, Kentos A, Timmers GJ, Regelink JC, Westerman M, de Heer K, Vekemans MM, Durdu-Rayman N, de Graauw NCHP, Seefat MR, van de Donk NWCJ, Ypma PF, Nasserinejad K, Zweegman S. Smits F, et al. Among authors: de waal egm. Blood Adv. 2025 Aug 22:bloodadvances.2025017394. doi: 10.1182/bloodadvances.2025017394. Online ahead of print. Blood Adv. 2025. PMID: 40845265
Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes.
Groen K, Smits F, Nasserinejad K, Levin MD, Regelink JC, Timmers GJ, de Waal EGM, Westerman M, Velders GA, de Heer K, Leys RBL, van Kampen RJW, Stege CAM, Seefat MR, Nijhof IS, van der Spek E, Klein SK, van de Donk NWCJ, Ypma PF, Zweegman S. Groen K, et al. Among authors: de waal egm. Hemasphere. 2024 Jul 4;8(7):e85. doi: 10.1002/hem3.85. eCollection 2024 Jul. Hemasphere. 2024. PMID: 38966208 Free PMC article. No abstract available.
Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial.
Groen K, Stege CAM, Nasserinejad K, de Heer K, van Kampen RJW, Leys RBL, Thielen N, Westerman M, Wu KL, Ludwig I, Issa DE, Velders GA, Vekemans MC, Timmers GJ, de Boer F, Tick LW, Verbrugge A, Buitenhuis D, Cunha SM, van der Spek E, de Waal EGM, Sohne M, Sonneveld P, Nijhof IS, Klein SK, van de Donk NWCJ, Levin MD, Ypma PF, Zweegman S. Groen K, et al. Among authors: de waal egm. EClinicalMedicine. 2023 Aug 29;63:102167. doi: 10.1016/j.eclinm.2023.102167. eCollection 2023 Sep. EClinicalMedicine. 2023. PMID: 37680948 Free PMC article.
Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study.
Stege CAM, Nasserinejad K, van der Spek E, Bilgin YM, Kentos A, Sohne M, van Kampen RJW, Ludwig I, Thielen N, Durdu-Rayman N, de Graauw NCHP, van de Donk NWCJ, de Waal EGM, Vekemans MC, Timmers GJ, van der Klift M, Soechit S, Geerts PAF, Silbermann MH, Oosterveld M, Nijhof IS, Sonneveld P, Klein SK, Levin MD, Zweegman S. Stege CAM, et al. Among authors: de waal egm. J Clin Oncol. 2021 Sep 1;39(25):2758-2767. doi: 10.1200/JCO.20.03143. Epub 2021 May 4. J Clin Oncol. 2021. PMID: 33945289 Clinical Trial.
Assessing differential application of thromboprophylaxis regimes related to risk of pulmonary embolism and mortality in COVID-19 patients through instrumental variable analysis.
Nab L, Visser C, van Bussel BCT, Beishuizen A, Bemelmans RHH, Ten Cate H, Croles FN, van Guldener C, de Jager CPC, Huisman MV, Nijziel MR, Kamphuisen PW, Klok FA, Koster SCE, Kuşadasi N, Meijer K, den Uil CA, Schutgens REG, Stam F, Vlaar APJ, Vlot EA, Linschoten MPM, Asselbergs FW, Kruip MJHA, le Cessie S, Cannegieter SC; Dutch Covid and Thrombosis Coalition & the CAPACITY-COVID collaborative consortium. Nab L, et al. Sci Rep. 2025 Mar 25;15(1):10321. doi: 10.1038/s41598-024-77858-w. Sci Rep. 2025. PMID: 40133355 Free PMC article.
13 results